
Sign up to save your podcasts
Or


Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:
By JAMA Network4.6
162162 ratings
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

38,614 Listeners

43,717 Listeners

27,188 Listeners

135 Listeners

321 Listeners

546 Listeners

697 Listeners

501 Listeners

6,434 Listeners

300 Listeners

264 Listeners

3,361 Listeners

20 Listeners

13 Listeners

10 Listeners

7 Listeners

20 Listeners

30 Listeners

90 Listeners

516 Listeners

369 Listeners

18 Listeners

369 Listeners